Infectious Diseases News and Research

RSS

MRSA survivors to share experience at World MRSA Day kickoff event

No one needs to explain to the people who have experienced it the danger posed by methicillin-resistant Staphylococcus aureus, the antibiotic-defying bacterium commonly known as MRSA. No one needs to explain to the people who have experienced it the danger posed by methicillin-resistant Staphylococcus aureus, the antibiotic-defying bacterium commonly known as MRSA.

29 Sep 2010

BAC completes feasibility study on CaptureSelect affinity ligands for Genmab

BAC BV, the leading provider of antibody-based affinity purification technology, today announced that it successfully completed a feasibility study in its collaboration with Genmab A/S (Copenhagen, Denmark), an international biotechnology company developing human antibody therapeutics for the potential treatment of cancer.

29 Sep 2010

Early initiation of ART may prevent immune system damage in HIV patients: Study

HIV-infected individuals who begin antiretroviral therapy (ART) soon after acquiring the virus may have stronger immune responses to other pathogens than HIV-infected individuals who begin ART later, a new study from the National Institutes of Health has found. This finding suggests that early initiation of ART may prevent irreversible immune system damage and adds to the body of evidence showing significant health benefits from early ART.

29 Sep 2010

Tamir's compounds perform better than Ganciclovir for Cytomegalovirus disease: Study

Tamir Biotechnology, Inc. announced today that scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) reported test results confirming two of our lead compounds outperformed market leader Roche's drug Ganciclovir in cell culture and plaque reduction assay (the gold standard) for Cytomegalovirus (CMV) disease. Additionally, antiviral activity was also apparent against other human herpesviruses, namely, HSV-1 (cold sores), HSV-2 (genital herpes), and Varicella-Zoster Virus (VZV) (chicken-pox and shingles).

29 Sep 2010

RV262 Phase I study launched to evaluate DNA prime/MVA vector boost vaccine regimen for HIV

A Phase I study, called RV262, recently began to evaluate a combination DNA prime/MVA vector boost vaccine regimen that was developed to protect against diverse subtypes of HIV-1 prevalent in North America, Europe, Africa and South America.

29 Sep 2010

NIH grants Akonni $3M for development of multi-drug resistant/extensively drug-resistant genotyping test

Akonni Biosystems, a molecular diagnostics company that develops, manufactures, and plans to market sophisticated genetic testing devices for complex infectious and human diseases, today announced receipt of a nearly $3 million Challenge Grant from the National Institutes of Health (NIH), a new program made possible under the American Recovery and Reinvestment Act (ARRA).

29 Sep 2010

PolyMedix begins PMX-30063 Phase 2 clinical trial for bacterial infections

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has initiated a Phase 2 clinical trial in Canada with its novel defensin-mimetic antibiotic, PMX-30063.

28 Sep 2010

NPL, Orla receives fund to improve detection methods for TB

Two UK companies have been awarded joint funding for a research project that could see significant advances in the quest to aid detection and eradication of Tuberculosis (TB), across the world.

28 Sep 2010

Many adults skip vaccines because of costs

The New York Times' Patient Money column examines the importance of vaccines for adults.

28 Sep 2010

IAVI investigators awarded grant to examine antibodies that neutralize HIV virus

A team of investigators headed by International AIDS Vaccine Initiative Investigator Pascal Poignard has been awarded a major grant from the National Institute of Allergy and Infectious Diseases of the US National Institutes of Health to investigate the biological mechanisms underlying the generation of broadly neutralizing antibodies by HIV positive individuals.

28 Sep 2010

BMC physicians receive $3M NIH grant to identify TB biomarkers

Boston Medical Center has been chosen to lead an investigation aimed at developing novel approaches to prevent tuberculosis. Jerrold J. Ellner, MD, chief of the section of infectious diseases at BMC and professor of medicine at the Boston University School of Medicine, a renowned expert in the field, will serve as principal investigator on the five-year, $3 million grant funded by the National Institutes of Health.

28 Sep 2010

BMC physicians to lead international research collaboration to curb infectious diseases

Boston Medical Center (BMC) has been chosen to lead an investigation aimed at developing novel approaches to prevent tuberculosis (TB). Jerrold J. Ellner, MD, chief of the section of infectious diseases at BMC and professor of medicine at the Boston University School of Medicine (BUSM), a renowned expert in the field, will serve as principal investigator (PI) on the five-year, $3 million grant funded by the National Institutes of Health (NIH).

27 Sep 2010

GBS pathogen suppresses immune cell function in newborn infants: Research

Group B Streptococcus (GBS), a bacterial pathogen that causes sepsis and meningitis in newborn infants, is able to shut down immune cell function in order to promote its own survival, according to researchers at the University of California, San Diego School of Medicine and the Skaggs School of Pharmacy and Pharmaceutical Sciences.

27 Sep 2010

HHS announces grants to support public health programs

Six months after the Affordable Care Act was signed into law, U.S. Department of Health and Human Services Secretary Kathleen Sebelius highlighted another important facet of the law today with the announcement of nearly $100 million in grants made possible primarily by the new law's Prevention and Public Health Fund.

27 Sep 2010

ARTES acquires ANAVAX virus-like particle technology from Select Vaccines

ARTES Biotechnology announces today the acquirement of the ANAVAX virus-like particle (VLP) technology from Select Vaccines Ltd. ANAVAX is a patent-protected VLP technology that can be applied to the prevention of several infectious diseases.

27 Sep 2010

Mayo Clinic initiates enrollment in first U.S. clinical Hand Transplant Program

Mayo Clinic has initiated the first clinical Hand Transplant Program in the United States and is now enrolling patients. This program offers hand transplantation as a clinically available option for patients with bilateral hand injuries or amputations. This allows patients to embark on this option of reconstructive surgery without being required to enroll in experimental trials.

24 Sep 2010

3M announces series of educational events to combat healthcare-associated infections

As a company on a mission to help hospitals fight healthcare-associated infections (HAIs), 3M Infection Prevention today announced a series of educational events taking place the week of September 27.

24 Sep 2010

Eastmont Community Center launches new adolescent immunization awareness initiative

Eastmont Community Center responded today to alarmingly low whooping cough and meningococcal meningitis immunization rates among Latino adolescents by launching a new adolescent immunization awareness initiative. The grassroots campaign aims to educate local Latino families about free or low-cost vaccines available to help protect children against these and other infectious diseases.

24 Sep 2010

NIH awards grants to treat HIV/AIDS in criminal justice system

Twelve scientific teams in more than a dozen states will receive National Institutes of Health (NIH) grants to study effective ways to prevent and treat HIV/AIDS among people in the criminal justice system.

24 Sep 2010

Cerus receives $1.4 million to support development of INTERCEPT red blood cell system

Cerus Corporation announced today that it has received an additional $1.4 million from the U.S. Department of Defense to support advanced development of the company's pathogen inactivation technology for red blood cells. The INTERCEPT red blood cell system is a pathogen inactivation product Cerus is developing to prevent the transmission of infectious diseases through red blood cell transfusions.

24 Sep 2010

Infectious Diseases News and Research

MRSA survivors to share experience at World MRSA Day kickoff event

BAC completes feasibility study on CaptureSelect affinity ligands for Genmab

Early initiation of ART may prevent immune system damage in HIV patients: Study

Tamir's compounds perform better than Ganciclovir for Cytomegalovirus disease: Study

RV262 Phase I study launched to evaluate DNA prime/MVA vector boost vaccine regimen for HIV

NIH grants Akonni $3M for development of multi-drug resistant/extensively drug-resistant genotyping test

PolyMedix begins PMX-30063 Phase 2 clinical trial for bacterial infections

NPL, Orla receives fund to improve detection methods for TB

Many adults skip vaccines because of costs

IAVI investigators awarded grant to examine antibodies that neutralize HIV virus

BMC physicians receive $3M NIH grant to identify TB biomarkers

BMC physicians to lead international research collaboration to curb infectious diseases

GBS pathogen suppresses immune cell function in newborn infants: Research

HHS announces grants to support public health programs

ARTES acquires ANAVAX virus-like particle technology from Select Vaccines

Mayo Clinic initiates enrollment in first U.S. clinical Hand Transplant Program

3M announces series of educational events to combat healthcare-associated infections

Eastmont Community Center launches new adolescent immunization awareness initiative

NIH awards grants to treat HIV/AIDS in criminal justice system

Cerus receives $1.4 million to support development of INTERCEPT red blood cell system

NGS for Infectious Disease Surveillance eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News